NINLARO (ixazomib) capsules, for oral use. Initial U.S. Approval: 2015

NINLARO (ixazomib) capsules, for oral use. Initial U.S. Approval: 2015

INDICATIONS AND USAGE
NINLARO is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
DOSAGE FORMS & STRENGTHS
Capsules: 4 mg, 3 mg, and 2.3 mg
Manufactured By: Takeda Pharmaceuticals America, Inc.
Prescribing Information URL: Click Here

Access to NINLARO ® (ixazomib) capsules, for oral use: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Ixazomib (trade name Ninlaro) is a drug for the treatment of multiple myeloma, a type of white blood cell cancer, in combination with other drugs. It is taken by mouth in the form of capsules.
The drug was developed by Takeda. In the US, it is approved since November 2015, and in the EU since November 2016.
Ixazomib is used in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adults after at least one prior therapy. There are no experiences with children and youths under 18 years of age.

Reviews

There are no reviews yet.

Add a review

neeraj
Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.